Skip to content

Homepage

Author: BridgeBio Pharma, Inc.

Posted Date:

May 4, 2026

BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026

BridgeBio Pharma, Inc.

May 4, 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

BridgeBio Pharma, Inc.

April 30, 2026
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

BridgeBio Pharma, Inc.

April 28, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc.

April 22, 2026
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio Pharma, Inc.

March 30, 2026
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9

BridgeBio Pharma, Inc.

March 30, 2026
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

BridgeBio Pharma, Inc.

March 23, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc.

March 20, 2026
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio Pharma, Inc.

March 11, 2026
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference

BridgeBio Pharma, Inc.

March 4, 2026

1 2 3